Hervycta plus 150 mg Injection
  1. Home
  2. Pharma Products
  3. Dr Reddy 's Laboratories Ltd
  4. Hervycta plus 150 mg Injection

Hervycta plus 150 mg Injection

Hervycta Plus 150 mg Injection contains trastuzumab 150 mg, a targeted anticancer medicine used for HER2-positive cancers. It is administered by a qualified healthcare professional through intravenous infusion as prescribed by the oncologist. Trastuzumab targets the HER2 protein and helps inhibit the growth of HER2-positive cancer cells.

BUY NOW

Category

Hervycta Plus 150 mg Injection is used in the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction cancer. Trastuzumab is a monoclonal antibody that binds to HER2 receptors and interferes with signaling involved in cancer-cell growth and survival. It may be used alone or with chemotherapy and other anticancer medicines depending on the prescribed treatment regimen. The dose and treatment schedule are determined by the treating oncologist according to the patient’s condition and response to therapy.

Technical Specification

Specification Details
Active Ingredient Trastuzumab
Strength 150 mg
Dosage Form Injection
Route Intravenous Infusion
Pack Size 1 Vial
Manufacturer/Marketer Dr. Reddy’s Laboratories Ltd.

Product Also Known As

Hervycta Plus 150 mg Injection, Hervycta Plus 150 Injection, Hervycta Plus Trastuzumab Injection, Trastuzumab 150 mg Injection, Trastuzumab HER2 Cancer Injection, Trastuzumab Targeted Therapy Injection